The other side of opioid receptor signalling: Regulation by protein- protein interaction

Current Drug Targets

Volumn 13, Issue 1, 2012, Pages 80-102

  Georgoussi, Zafiroula ^a   Georganta, Eirini Maria ^a   Milligan, Graeme ^b  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cellular signalling; G protein; G protein coupled receptors; Interacting proteins; Internalization; Opioid; Signalling complex; Trafficking

Indexed keywords

DELTA OPIATE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPIATE; OPIATE RECEPTOR;

CELLULAR DISTRIBUTION; CYTOSKELETON; NOCICEPTION; PAIN THRESHOLD; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GTP-BINDING PROTEINS; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 84855841547     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012798868470     Document Type: Review

References (296)

1. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The deltaopioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-52.
2. Evans CJ, Keith DE, Jr., Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-5.
3. Knapp RJ, Malatynska E, Collins N, et al. Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995; 9: 516-25.
4. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18: 22-9.
5. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001; 81: 299-343.
6. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56: 351-69.
7. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008; 154: 384-96.
8. Lipkowski AW, Carr, D.B. Rethinking opioid equivalence. Pain. Clinical Updates 2002; 10: 1-4.
9. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73: 953-90.
10. Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005; 5: 60-8.
11. Georgoussi Z, Zioudrou C. Effect of delta-opioid antagonists on the functional coupling between opioid receptors and G-proteins in rat brain membranes. Biochem Pharmacol 1993; 45: 2405-10.
12. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40: 389-430.
13. Standifer KM, Pasternak GW. G proteins and opioid receptormediated signalling. Cell Signal 1997; 9: 237-48.
14. Lo RK, Wong YH. Signal transducer and activator of transcription 3 activation by the delta-opioid receptor via Galpha14 involves multiple intermediates. Mol Pharmacol 2004; 65: 1427-39.
15. Mazarakou G, Georgoussi Z. STAT5A interacts with and is phosphorylated upon activation of the mu-opioid receptor. J Neurochem 2005; 93: 918-31.
16. Law PY, Wong YH, Loh HH. Mutational analysis of the structure and function of opioid receptors. Biopolymers 1999; 51: 440-55.
17. Burt AR, Carr IC, Mullaney I, Anderson NG, Milligan G. Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse delta opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. Biochem J 1996; 320 (Pt 1): 227-35.
18. Swevers L, Morou E, Balatsos N, Iatrou K, Georgoussi Z. Functional expression of mammalian opioid receptors in insect cells and high-throughput screening platforms for receptor ligand mimetics. Cell Mol Life Sci 2005; 62: 919-30.
19. Georgoussi Z, Carr C, Milligan G. Direct measurements of in situ interactions of rat brain opioid receptors with the guanine nucleotide-binding protein Go. Mol Pharmacol 1993; 44: 62-9.
20. Georgoussi Z, Milligan G, Zioudrou C. Immunoprecipitation of opioid receptor-Go-protein complexes using specific GTP-bindingprotein antisera. Biochem J 1995; 306 (Pt 1): 71-5.
21. Chan JS, Chiu TT, Wong YH. Activation of type II adenylyl cyclase by the cloned mu-opioid receptor: coupling to multiple G proteins. J Neurochem 1995; 65: 2682-9.
22. Garzon J, Garcia-Espana A, Sanchez-Blazquez P. Opioids binding mu and delta receptors exhibit diverse efficacy in the activation of Gi2 and G(x/z) transducer proteins in mouse periaqueductal gray matter. J Pharmacol Exp Ther 1997; 281: 549-57.
23. Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 2001; 54: 229-35.
24. Tso PH, Wong YH. Molecular basis of opioid dependence: role of signal regulation by G-proteins. Clin Exp Pharmacol Physiol 2003; 30: 307-16.
25. McKenzie FR, Milligan G. Delta-opioid-receptor-mediated inhibition of adenylate cyclase is transduced specifically by the guanine-nucleotide-binding protein Gi2. Biochem J 1990; 267: 391-8.
26. Merkouris M, Mullaney I, Georgoussi Z, Milligan G. Regulation of spontaneous activity of the delta-opioid receptor: studies of inverse agonism in intact cells. J Neurochem 1997; 69: 2115-22.
27. Milligan G. Opioid receptors and their interacting proteins. Neuromolecular Med 2005; 7: 51-9.
28. Georgoussi Z. In: Molecular Aspects of G Protein-Coupled Receptors Ed.: Nova Science Publishers Inc 2008; pp. 169-206.
29. Milligan G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discov Today 2006; 11: 541-9.
30. Cvejic S, Devi LA. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem 1997; 272: 26959-64.
31. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700.
32. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci U S A 2001; 98: 343-8.
33. George SR, Fan T, Xie Z, et al. Oligomerization of mu-and deltaopioid receptors. Generation of novel functional properties. J Biol Chem 2000; 275: 26128-35.
34. Ramsay D, Kellett E, McVey M, Rees S, Milligan G. Homo-and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): heterooligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 2002; 365: 429-40.
35. Law PY, Erickson-Herbrandson LJ, Zha QQ, et al. Heterodimerization of mu-and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 2005; 280: 11152-64.
36. Pascal G, Milligan G. Functional complementation and the analysis of opioid receptor homodimerization. Mol Pharmacol 2005; 68: 905-15.
37. Milligan G. High-content assays for ligand regulation of G-proteincoupled receptors. Drug Discov Today 2003; 8: 579-85.
38. Douris V, Swevers L, Labropoulou V, Andronopoulou E, Georgoussi Z, Iatrou K. Stably transformed insect cell lines: tools for expression of secreted and membrane-anchored proteins and high-throughput screening platforms for drug and insecticide discovery. Adv Virus Res 2006; 68: 113-56.
39. Tolkovsky AM, Levitzki A. Mode of coupling between the betaadrenergic receptor and adenylate cyclase in turkey erythrocytes. Biochemistry 1978; 17: 3795.
40. Luttrell LM, Ostrowski J, Cotecchia S, Kendall H, Lefkowitz RJ. Antagonism of catecholamine receptor signaling by expression of cytoplasmic domains of the receptors. Science 1993; 259: 1453-7.
41. Hawes BE, Luttrell LM, Exum ST, Lefkowitz RJ. Inhibition of G protein-coupled receptor signaling by expression of cytoplasmic domains of the receptor. J Biol Chem 1994; 269: 15776-85.
42. Morou E, Georgoussi Z. Expression of the third intracellular loop of the delta-opioid receptor inhibits signaling by opioid receptors and other G protein-coupled receptors. J Pharmacol Exp Ther 2005; 315: 1368-79.
43. Lee NH, Geoghagen NS, Cheng E, Cline RT, Fraser CM. Alanine scanning mutagenesis of conserved arginine/lysine-arginine/lysine-X-X-arginine/lysine G protein-activating motifs on m1 muscarinic acetylcholine receptors. Mol Pharmacol 1996; 50: 140-8.
44. Georgoussi Z, Merkouris M, Mullaney I, et al. Selective interactions of mu-opioid receptors with pertussis toxin-sensitive G proteins: involvement of the third intracellular loop and the cterminal tail in coupling. Biochim Biophys Acta 1997; 1359: 263-74.
45. Megaritis G, Merkouris M, Georgoussi Z. Functional domains of delta-and mu-opioid receptors responsible for adenylyl cyclase inhibition. Receptors Channels 2000; 7: 199-212.
46. Merkouris M, Dragatsis I, Megaritis G, et al. Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides. Mol Pharmacol 1996; 50: 985-93.
47. Georgoussi Z, Leontiadis L, Mazarakou G, Merkouris M, Hyde K, Hamm H. Selective interactions between G protein subunits and RGS4 with the C-terminal domains of the mu-and delta-opioid receptors regulate opioid receptor signaling. Cell Signal 2006; 18: 771-82.
48. Bockaert J, Marin P, Dumuis A, Fagni L. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett 2003; 546: 65-72.
49. Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP). Pharmacol Ther 2004; 103: 203-21.
50. Hall RA, Premont RT, Lefkowitz RJ. Heptahelical receptor signaling: beyond the G protein paradigm. J Cell Biol 1999; 145: 927-32.
51. Milligan G, White JH. Protein-protein interactions at G-proteincoupled receptors. Trends Pharmacol Sci 2001; 22: 513-8.
52. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal 2002; 14: 297-309.
53. Ciruela F, Canela L, Burgueno J, et al. Heptaspanning membrane receptors and cytoskeletal/scaffolding proteins: focus on adenosine, dopamine, and metabotropic glutamate receptor function. J Mol Neurosci 2005; 26: 277-92.
54. Hall RA. Beta-adrenergic receptors and their interacting proteins. Semin Cell Dev Biol 2004; 15: 281-8.
55. Tilakaratne N, Sexton PM. G-Protein-coupled receptor-protein interactions: basis for new concepts on receptor structure and function. Clin Exp Pharmacol Physiol 2005; 32: 979-87.
56. Chaipatikul V, Loh HH, Law PY. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain. J Pharmacol Exp Ther 2003; 305: 909-18.
57. Wang D, Sadee W, Quillan JM. Calmodulin binding to G proteincoupling domain of opioid receptors. J Biol Chem 1999; 274: 22081-8.
58. Van Eldik LJ, Watterson DM. Calmodulin and calcium signal transduction: an introduction. New York: Academic Press 1998.
59. Wang D, Surratt CK, Sadee W. Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3) in morphine-pretreated cell. J Neurochem 2000; 75: 763-71.
60. Smart D, Smith G, Lambert DG. mu-Opioid receptor stimulation of inositol (1,4,5)trisphosphate formation via a pertussis toxinsensitive G protein. J Neurochem 1994; 62: 1009-14.
61. Samways DS, Henderson G. Opioid elevation of intracellular free calcium: possible mechanisms and physiological relevance. Cell Signal 2006; 18: 151-61.
62. Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, Freissmuth M, Nanoff C. Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J Biol Chem 2000; 275: 32672-80.
63. Liu Y, Buck DC, Macey TA, Lan H, Neve KA. Evidence that calmodulin binding to the dopamine D2 receptor enhances receptor signaling. J Recept Signal Transduct Res 2007; 27: 47-65.
64. El Far O, Bofill-Cardona E, Airas JM, et al. Mapping of calmodulin and Gbetagamma binding domains within the Cterminal region of the metabotropic glutamate receptor 7A. J Biol Chem 2001; 276: 30662-9.
65. Labasque M, Reiter E, Becamel C, Bockaert J, Marin P. Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestindependent receptor signaling. Mol Biol Cell 2008; 19: 4640-50.
66. Feng GJ, Kellett E, Scorer CA, Wilde J, White JH, Milligan G. Selective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activation. J Biol Chem 2003; 278: 33400-7.
67. Ruhrberg C, Hajibagheri MA, Parry DA, Watt FM. Periplakin, a novel component of cornified envelopes and desmosomes that belongs to the plakin family and forms complexes with envoplakin. J Cell Biol 1997; 139: 1835-49.
68. Leung CL, Green KJ, Liem RK. Plakins: a family of versatile cytolinker proteins. Trends Cell Biol 2002; 12: 37-45.
69. Marin EP, Krishna AG, Zvyaga TA, Isele J, Siebert F, Sakmar TP. The amino terminus of the fourth cytoplasmic loop of rhodopsin modulates rhodopsin-transducin interaction. J Biol Chem 2000; 275: 1930-6.
70. Murdoch H, Feng GJ, Bachner D, et al. Periplakin interferes with G protein activation by the melanin-concentrating hormone receptor-1 by binding to the proximal segment of the receptor Cterminal tail. J Biol Chem 2005; 280: 8208-20.
71. Milligan G, Murdoch H, Kellett E, White JH, Feng GJ. Interactions between G-protein-coupled receptors and periplakin: a selective means to regulate G-protein activation. Biochem Soc Trans 2004; 32: 878-80.
72. Ward RJ, Jenkins L, Milligan G. Selectivity and functional consequences of interactions of family A G protein-coupled receptors with neurochondrin and periplakin. J Neurochem 2009; 109: 182-92.
73. De Vries L, Zheng B, Fischer T, Elenko E, Farquhar MG. The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol 2000; 40: 235-71.
74. Abramow-Newerly M, Roy AA, Nunn C, Chidiac P. RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal 2006; 18: 579-91.
75. Neubig RR, Siderovski DP. Regulators of G-protein signalling as new central nervous system drug targets. Nat Rev Drug Discov 2002; 1: 187-97.
76. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002; 54: 527-59.
77. Bansal G, Druey KM, Xie Z. R4 RGS proteins: regulation of Gprotein signaling and beyond. Pharmacol Ther 2007; 116: 473-95.
78. Hepler JR. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999; 20: 376-82.
79. Chidiac P, Roy AA. Activity, regulation, and intracellular localization of RGS proteins. Receptors Channels 2003; 9: 135-47.
80. Neitzel KL, Hepler JR. Cellular mechanisms that determine selective RGS protein regulation of G protein-coupled receptor signaling. Semin Cell Dev Biol 2006; 17: 383-9.
81. Bernstein LS, Ramineni S, Hague C, et al. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. J Biol Chem 2004; 279: 21248-56.
82. Hague C, Bernstein LS, Ramineni S, Chen Z, Minneman KP, Hepler JR. Selective inhibition of alpha1A-adrenergic receptor signaling by RGS2 association with the receptor third intracellular loop. J Biol Chem 2005; 280: 27289-95.
83. Schwendt M, McGinty JF. Regulator of G-protein signaling 4 interacts with metabotropic glutamate receptor subtype 5 in rat striatum: relevance to amphetamine behavioral sensitization. J Pharmacol Exp Ther 2007; 323: 650-7.
84. Xie GX, Palmer PP. RGS proteins: new players in the field of opioid signaling and tolerance mechanisms. Anesth Analg 2005; 100: 1034-42.
85. Gold SJ, Han MH, Herman AE, et al. Regulation of RGS proteins by chronic morphine in rat locus coeruleus. Eur J Neurosci 2003; 17: 971-80.
86. Nakagawa T, Minami M, Satoh M. Up-regulation of RGS4 mRNA by opioid receptor agonists in PC12 cells expressing cloned mu-or kappa-opioid receptors. Eur J Pharmacol 2001; 433: 29-36.
87. Leontiadis LJ, Papakonstantinou MP, Georgoussi Z. Regulator of G protein signaling 4 confers selectivity to specific G proteins to modulate mu-and delta-opioid receptor signaling. Cell Signal 2009; 21: 1218-28.
88. Popov S, Yu K, Kozasa T, Wilkie TM. The regulators of G protein signaling (RGS) domains of RGS4, RGS10, and GAIP retain GTPase activating protein activity in vitro. Proc Natl Acad Sci U S A 1997; 94: 7216-20.
89. Bahia DS, Sartania N, Ward RJ, et al. Concerted stimulation and deactivation of pertussis toxin-sensitive G proteins by chimeric G protein-coupled receptor-regulator of G protein signaling 4 fusion proteins: analysis of the contribution of palmitoylated cysteine residues to the GAP activity of RGS4. J Neurochem 2003; 85: 1289-98.
90. Belcheva MM, Haas PD, Tan Y, Heaton VM, Coscia CJ. The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells. J Pharmacol Exp Ther 2002; 303: 909-18.
91. Druey KM, Blumer KJ, Kang VH, Kehrl JH. Inhibition of Gprotein-mediated MAP kinase activation by a new mammalian gene family. Nature 1996; 379: 742-6.
92. Yan Y, Chi PP, Bourne HR. RGS4 inhibits Gq-mediated activation of mitogen-activated protein kinase and phosphoinositide synthesis. J Biol Chem 1997; 272: 11924-7.
93. Leone AM, Errico M, Lin SL, Cowen DS. Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT(1B) receptors in transfected BE(2)-C neuroblastoma cells is inhibited by RGS4. J Neurochem 2000; 75: 934-8.
94. Anger T, Klintworth N, Stumpf C, Daniel WG, Mende U, Garlichs CD. RGS protein specificity towards Gq-and Gi/o-mediated ERK 1/2 and Akt activation, in vitro. J Biochem Mol Biol 2007; 40: 899-910.
95. Clark MJ, Harrison C, Zhong H, Neubig RR, Traynor JR. Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signalregulated kinases, and intracellular calcium pathways. J Biol Chem 2003; 278: 9418-25.
96. Talbot JN, Roman DL, Clark MJ, et al. Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent. J Neurochem 112: 1026-34.
97. Kieffer BL, Evans CJ. Opioid tolerance-in search of the holy grail. Cell 2002; 108: 587-90.
98. Lopez-Gimenez JF, Milligan G. Opioid regulation of mu receptor internalisation: relevance to the development of tolerance and dependence. CNS & Neurological Disorders-Drug Targets 2010; in press.
99. Grillet N, Pattyn A, Contet C, Kieffer BL, Goridis C, Brunet JF. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol 2005; 25: 4221-8.
100. Han MH, Renthal W, Ring RH, et al. Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biol Psychiatry 2010; 67: 761-9.
101. Elenko E, Fischer T, Niesman I, et al. Spatial regulation of Galphai protein signaling in clathrin-coated membrane microdomains containing GAIP. Mol Pharmacol 2003; 64: 11-20.
102. Rodriguez-Munoz M, de la Torre-Madrid E, Gaitan G, Sanchez-Blazquez P, Garzon J. RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons. Cell Signal 2007; 19: 2558-71.
103. Jaen C, Doupnik CA. RGS3 and RGS4 differentially associate with G protein-coupled receptor-Kir3 channel signaling complexes revealing two modes of RGS modulation. Precoupling and collision coupling. J Biol Chem 2006; 281: 34549-60.
104. Zeng W, Xu X, Popov S, et al. The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling. J Biol Chem 1998; 273: 34687-90.
105. Srinivasa SP, Bernstein LS, Blumer KJ, Linder ME. Plasma membrane localization is required for RGS4 function in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1998; 95: 5584-9.
106. Jin Y, Zhong H, Omnaas JR, Neubig RR, Mosberg HI. Structurebased design, synthesis, and pharmacologic evaluation of peptide RGS4 inhibitors. J Pept Res 2004; 63: 141-6.
107. Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol Pharmacol 2007; 71: 169-75.
108. Kimple AJ, Willard FS, Giguere PM, Johnston CA, Mocanu V, Siderovski DP. The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face. Biochim Biophys Acta 2007; 1774: 1213-20.
109. Gold SJ, Ni YG, Dohlman HG, Nestler EJ. Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. J Neurosci 1997; 17: 8024-37.
110. Thomas EA, Danielson PE, Sutcliffe JG. RGS9: a regulator of Gprotein signalling with specific expression in rat and mouse striatum. J Neurosci Res 1998; 52: 118-24.
111. Zachariou V, Georgescu D, Sanchez N, et al. Essential role for RGS9 in opiate action. Proc Natl Acad Sci USA 2003; 100: 13656-61.
112. Rahman Z, Gold SJ, Potenza MN, et al. Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene. J Neurosci 1999; 19: 2016-26.
113. Rahman Z, Schwarz J, Gold SJ, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 2003; 38: 941-52.
114. Cabrera-Vera TM, Hernandez S, Earls LR, et al. RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. Proc Natl Acad Sci U S A 2004; 101: 16339-44.
115. Mancuso JJ, Qian Y, Long C, Wu GY, Wensel TG. Distribution of RGS9-2 in neurons of the mouse striatum. J Neurochem 112: 651-61.
116. Garzon J, Rodriguez-Diaz M, Lopez-Fando A, Sanchez-Blazquez P. RGS9 proteins facilitate acute tolerance to mu-opioid effects. Eur J Neurosci 2001; 13: 801-11.
117. Garzon J, Rodriguez-Munoz M, Sanchez-Blazquez P. Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter. Neuropharmacology 2005; 48: 853-68.
118. Garzon J, Rodriguez-Munoz M, Lopez-Fando A, Sanchez-Blazquez P. Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization. J Biol Chem 2005; 280: 8951-60.
119. Garzon J, Rodriguez-Munoz M, de la Torre-Madrid E, Sanchez-Blazquez P. Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS. Psychopharmacology (Berl) 2005; 180: 1-11.
120. Psifogeorgou K, Papakosta P, Russo SJ, et al. RGS9-2 is a negative modulator of mu-opioid receptor function. J Neurochem 2007; 103: 617-25.
121. Kovoor A, Seyffarth P, Ebert J, et al. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci 2005; 25: 2157-65.
122. Garzon J, Rodriguez-Munoz M, Lopez-Fando A, Sanchez-Blazquez P. The RGSZ2 protein exists in a complex with muopioid receptors and regulates the desensitizing capacity of Gz proteins. Neuropsychopharmacology 2005; 30: 1632-48.
123. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005; 308: 512-7.
124. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483-510.
125. Cen B, Yu Q, Guo J, et al. Direct binding of beta-arrestins to two distinct intracellular domains of the delta opioid receptor. J Neurochem 2001; 76: 1887-94.
126. Cheng ZJ, Yu QM, Wu YL, Ma L, Pei G. Selective interference of beta-arrestin 1 with kappa and delta but not mu opioid receptor/G protein coupling. J Biol Chem 1998; 273: 24328-33.
127. Lohse MJ, Andexinger S, Pitcher J, et al. Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. J Biol Chem 1992; 267: 8558-64.
128. Ferguson SS, Downey WE, 3rd, Colapietro AM, Barak LS, Menard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996; 271: 363-6.
129. Kovoor A, Nappey V, Kieffer BL, Chavkin C. Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in xenopus oocytes. J Biol Chem 1997; 272: 27605-11.
130. Wu G, Krupnick JG, Benovic JL, Lanier SM. Interaction of arrestins with intracellular domains of muscarinic and alpha2-adrenergic receptors. J Biol Chem 1997; 272: 17836-42.
131. Gelber EI, Kroeze WK, Willins DL, et al. Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: the third intracellular loop is alpha-helical and binds purified arrestins. J Neurochem 1999; 72: 2206-14.
132. Cheng ZJ, Zhao J, Sun Y, et al. beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem 2000; 275: 2479-85.
133. Kim OJ, Gardner BR, Williams DB, et al. The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J Biol Chem 2004; 279: 7999-8010.
134. Zhang X, Wang F, Chen X, et al. Beta-arrestin1 and beta-arrestin2 are differentially required for phosphorylation-dependent and-independent internalization of delta-opioid receptors. J Neurochem 2005; 95: 169-78.
135. Navratilova E, Waite S, Stropova D, et al. Quantitative evaluation of human delta opioid receptor desensitization using the operational model of drug action. Mol Pharmacol 2007; 71: 1416-26.
136. Qiu Y, Loh HH, Law PY. Phosphorylation of the delta-opioid receptor regulates its beta-arrestins selectivity and subsequent receptor internalization and adenylyl cyclase desensitization. J Biol Chem 2007; 282: 22315-23.
137. Zhang X, Wang F, Chen X, Chen Y, Ma L. Post-endocytic fates of delta-opioid receptor are regulated by GRK2-mediated receptor phosphorylation and distinct beta-arrestin isoforms. J Neurochem 2008; 106: 781-92.
138. Gurevich VV, Gurevich EV. The structural basis of arrestinmediated regulation of G-protein-coupled receptors. Pharmacol Ther 2006; 110: 465-502.
139. Keith DE, Murray SR, Zaki PA, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996; 271: 19021-4.
140. Zhang J, Ferguson SS, Barak LS, et al. Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci U S A 1998; 95: 7157-62.
141. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol Sci 2007; 28: 416-22.
142. Molinari P, Vezzi V, Sbraccia M, et al. Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 2010; 285: 12522-35.
143. McPherson J, Rivero G, Baptist M, et al. mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 2010; 78: 756-66.
144. Bruns IR, Chhum S, Dinh AT, et al. A potential novel strategy to separate therapeutic-and side-effects that are mediated via the same receptor: beta-arrestin2/G-protein coupling antagonists. J Clin Pharm Ther 2006; 31: 119-28.
145. Groer CE, Tidgewell K, Moyer RA, et al. An opioid agonist that does not induce micro-opioid receptor--arrestin interactions or receptor internalization. Mol Pharmacol 2007; 71: 549-57.
146. Raehal KM, Walker JK, Bohn LM. Morphine side effects in betaarrestin 2 knockout mice. J Pharmacol Exp Ther 2005; 314: 1195-201.
147. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000; 408: 720-3.
148. Tidgewell K, Groer CE, Harding WW, et al. Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem 2008; 51: 2421-31.
149. Lopez-Gimenez JF, Vilaro MT, Milligan G. Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation. Mol Pharmacol 2008; 74: 1278-91.
150. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB. Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 1997; 272: 28869-74.
151. Whistler JL, Tsao P, von Zastrow M. A phosphorylation-regulated brake mechanism controls the initial endocytosis of opioid receptors but is not required for post-endocytic sorting to lysosomes. J Biol Chem 2001; 276: 34331-8.
152. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 1998; 273: 18677-80.
153. Pei G, Kieffer BL, Lefkowitz RJ, Freedman NJ. Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C. Mol Pharmacol 1995; 48: 173-7.
154. Zhang J, Barak LS, Anborgh PH, Laporte SA, Caron MG, Ferguson SS. Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic complexes. J Biol Chem 1999; 274: 10999-1006.
155. Wang Z, Sadee W. Tolerance to morphine at the mu-opioid receptor differentially induced by cAMP-dependent protein kinase activation and morphine. Eur J Pharmacol 2000; 389: 165-71.
156. Appleyard SM, McLaughlin JP, Chavkin C. Tyrosine phosphorylation of the kappa-opioid receptor regulates agonist efficacy. J Biol Chem 2000; 275: 38281-5.
157. Kramer HK, Andria ML, Kushner SA, Esposito DH, Hiller JM, Simon EJ. Mutation of tyrosine 318 (Y318F) in the delta-opioid receptor attenuates tyrosine phosphorylation, agonist-dependent receptor internalization, and mitogen-activated protein kinase activation. Brain Res Mol Brain Res 2000; 79: 55-66.
158. Guang W, Wang H, Su T, Weinstein IB, Wang JB. Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Mol Pharmacol 2004; 66: 1285-92.
159. Lima CD, Klein MG, Hendrickson WA. Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science 1997; 278: 286-90.
160. Klein MG, Yao Y, Slosberg ED, Lima CD, Doki Y, Weinstein IB. Characterization of PKCI and comparative studies with FHIT, related members of the HIT protein family. Exp Cell Res 1998; 244: 26-32.
161. Su T, Suzui M, Wang L, Lin CS, Xing WQ, Weinstein IB. Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci U S A 2003; 100: 7824-9.
162. Ajit SK, Ramineni S, Edris W, et al. RGSZ1 interacts with protein kinase C interacting protein PKCI-1 and modulates mu opioid receptor signaling. Cell Signal 2007; 19: 723-30.
163. Bailey CP, Llorente J, Gabra BH, et al. Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci 2009; 29: 307-18.
164. Bailey CP, Oldfield S, Llorente J, et al. Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol 2009; 158: 157-64.
165. Zheng H, Chu J, Zhang Y, Loh HH, Law PY. Modulating μ-Opioid Receptor Phosphorylation Switches Agonist-Dependent Signaling as Reflected in PKCε Activation and Dendritic Spine Stability. J Biol Chem 2011; in press.
166. Liscovitch M, Czarny M, Fiucci G, Lavie Y, Tang X. Localization and possible functions of phospholipase D isozymes. Biochim Biophys Acta 1999; 1439: 245-63.
167. Exton JH. Regulation of phospholipase D. FEBS Lett 2002; 531: 58-61.
168. Bhattacharya M, Babwah AV, Ferguson SS. Small GTP-binding protein-coupled receptors. Biochem Soc Trans 2004; 32: 1040-4.
169. Du G, Huang P, Liang BT, Frohman MA. Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis. Mol Biol Cell 2004; 15: 1024-30.
170. Koch T, Brandenburg LO, Schulz S, Liang Y, Klein J, Hollt V. ADP-ribosylation factor-dependent phospholipase D2 activation is required for agonist-induced mu-opioid receptor endocytosis. J Biol Chem 2003; 278: 9979-85.
171. Mitchell R, McCulloch D, Lutz E, et al. Rhodopsin-family receptors associate with small G proteins to activate phospholipase D. Nature 1998; 392: 411-4.
172. Rankovic M, Jacob L, Rankovic V, et al. ADP-ribosylation factor 6 regulates mu-opioid receptor trafficking and signaling via activation of phospholipase D2. Cell Signal 2009; 21: 1784-93.
173. Koch T, Brandenburg LO, Liang Y, et al. Phospholipase D2 modulates agonist-induced mu-opioid receptor desensitization and resensitization. J Neurochem 2004; 88: 680-8.
174. Koch T, Wu DF, Yang LQ, Brandenburg LO, Hollt V. Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. J Neurochem 2006; 97: 365-72.
175. Koch T, Seifert A, Wu DF, et al. mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem 2009; 110: 1288-96.
176. Yokoyama N, Hayashi N, Seki T, et al. A giant nucleopore protein that binds Ran/TC4. Nature 1995; 376: 184-8.
177. Nishitani H, Hirose E, Uchimura Y, et al. Full-sized RanBPM cDNA encodes a protein possessing a long stretch of proline and glutamine within the N-terminal region, comprising a large protein complex. Gene 2001; 272: 25-33.
178. Murrin LC, Talbot JN. RanBPM, a scaffolding protein in the immune and nervous systems. J Neuroimmune Pharmacol 2007; 2: 290-5.
179. Denti S, Sirri A, Cheli A, et al. RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1. J Biol Chem 2004; 279: 13027-34.
180. Nakamura M, Masuda H, Horii J, et al. When overexpressed, a novel centrosomal protein, RanBPM, causes ectopic microtubule nucleation similar to gamma-tubulin. J Cell Biol 1998; 143: 1041-52.
181. Mikolajczyk M, Shi J, Vaillancourt RR, Sachs NA, Nelson M. The cyclin-dependent kinase 11(p46) isoform interacts with RanBPM. Biochem Biophys Res Commun 2003; 310: 14-8.
182. Bai D, Chen H, Huang BR. RanBPM is a novel binding protein for p75NTR. Biochem Biophys Res Commun 2003; 309: 552-7.
183. Wang D, Li Z, Messing EM, Wu G. Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem 2002; 277: 36216-22.
184. Ideguchi H, Ueda A, Tanaka M, et al. Structural and functional characterization of the USP11 deubiquitinating enzyme, which interacts with the RanGTP-associated protein RanBPM. Biochem J 2002; 367: 87-95.
185. Talbot JN, Skifter DA, Bianchi E, Monaghan DT, Toews ML, Murrin LC. Regulation of mu opioid receptor internalization by the scaffold protein RanBPM. Neurosci Lett 2009; 466: 154-8.
186. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci U S A 1998; 95: 9914-9.
187. Sternini C, Spann M, Anton B, et al. Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A 1996; 93: 9241-6.
188. Fischer BD, Miller LL, Henry FE, Picker MJ, Dykstra LA. Increased efficacy of micro-opioid agonist-induced antinociception by metabotropic glutamate receptor antagonists in C57BL/6 mice: comparison with (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959). Psychopharmacology (Berl) 2008; 198: 271-8.
189. Nielsen DA, Ji F, Yuferov V, et al. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry 2008; 13: 417-28.
190. Ogawa M, Miyakawa T, Nakamura K, et al. Altered sensitivities to morphine and cocaine in scaffold protein tamalin knockout mice. Proc Natl Acad Sci U S A 2007; 104: 14789-94.
191. Seebahn A, Rose M, Enz R. RanBPM is expressed in synaptic layers of the mammalian retina and binds to metabotropic glutamate receptors. FEBS Lett 2008; 582: 2453-7.
192. Brady AE, Wang Q, Allen PB, Rizzo M, Greengard P, Limbird LE. Alpha 2-adrenergic agonist enrichment of spinophilin at the cell surface involves beta gamma subunits of Gi proteins and is preferentially induced by the alpha 2A-subtype. Mol Pharmacol 2005; 67: 1690-6.
193. Allen PB, Ouimet CC, Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc Natl Acad Sci USA 1997; 94: 9956-61.
194. Satoh A, Nakanishi H, Obaishi H, et al. Neurabin-II/spinophilin. An actin filament-binding protein with one pdz domain localized at cadherin-based cell-cell adhesion sites. J Biol Chem 1998; 273: 3470-5.
195. Sarrouilhe D, di Tommaso A, Metaye T, Ladeveze V. Spinophilin: from partners to functions. Biochimie 2006; 88: 1099-113.
196. Wang Q, Limbird LE. Regulation of alpha2AR trafficking and signaling by interacting proteins. Biochem Pharmacol 2007; 73: 1135-45.
197. Brady AE, Wang Q, Colbran RJ, Allen PB, Greengard P, Limbird LE. Spinophilin stabilizes cell surface expression of alpha 2Badrenergic receptors. J Biol Chem 2003; 278: 32405-12.
198. Fujii S, Yamazoe G, Itoh M, Kubo Y, Saitoh O. Spinophilin inhibits the binding of RGS8 to M1-mAChR but enhances the regulatory function of RGS8. Biochem Biophys Res Commun 2008; 377: 200-4.
199. Charlton JJ, Allen PB, Psifogeorgou K, et al. Multiple actions of spinophilin regulate mu opioid receptor function. Neuron 2008; 58: 238-47.
200. Law PY, Loh HH. Regulation of opioid receptor activities. J Pharmacol Exp Ther 1999; 289: 607-24.
201. Tsao PI, von Zastrow M. Type-specific sorting of G proteincoupled receptors after endocytosis. J Biol Chem 2000; 275: 11130-40.
202. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001; 32: 829-39.
203. Whistler JL, Enquist J, Marley A, et al. Modulation of postendocytic sorting of G protein-coupled receptors. Science 2002; 297: 615-20.
204. Heydorn A, Sondergaard BP, Ersboll B, et al. A library of 7TM receptor C-terminal tails. Interactions with the proposed postendocytic sorting proteins ERM-binding phosphoprotein 50 (EBP50), N-ethylmaleimide-sensitive factor (NSF), sorting nexin 1 (SNX1), and G protein-coupled receptor-associated sorting protein (GASP). J Biol Chem 2004; 279: 54291-303.
205. Simonin F, Karcher P, Boeuf JJ, Matifas A, Kieffer BL. Identification of a novel family of G protein-coupled receptor associated sorting proteins. J Neurochem 2004; 89: 766-75.
206. Tetsuka M, Saito Y, Imai K, Doi H, Maruyama K. The basic residues in the membrane-proximal C-terminal tail of the rat melanin-concentrating hormone receptor 1 are required for receptor function. Endocrinology 2004; 145: 3712-23.
207. Zhong M, Navratil AM, Clay C, Sanborn BM. Residues in the hydrophilic face of putative helix 8 of oxytocin receptor are important for receptor function. Biochemistry 2004; 43: 3490-8.
208. Thompson D, Pusch M, Whistler JL. Changes in G protein-coupled receptor sorting protein affinity regulate postendocytic targeting of G protein-coupled receptors. J Biol Chem 2007; 282: 29178-85.
209. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001; 276: 24232-41.
210. Marley A, von Zastrow M. Dysbindin promotes the post-endocytic sorting of G protein-coupled receptors to lysosomes. PLoS One 5: e9325.
211. Liang YJ, Wu DF, Yang LQ, Hollt V, Koch T. Interaction of the mu-opioid receptor with synaptophysin influences receptor trafficking and signaling. Mol Pharmacol 2007; 71: 123-31.
212. Sudhof TC, Lottspeich F, Greengard P, Mehl E, Jahn R. A synaptic vesicle protein with a novel cytoplasmic domain and four transmembrane regions. Science 1987; 238: 1142-4.
213. Valtorta F, Pennuto M, Bonanomi D, Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays 2004; 26: 445-53.
214. Thiele C, Hannah MJ, Fahrenholz F, Huttner WB. Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol 2000; 2: 42-9.
215. Daly C, Ziff EB. Ca2+-dependent formation of a dynaminsynaptophysin complex: potential role in synaptic vesicle endocytosis. J Biol Chem 2002; 277: 9010-5.
216. Slepnev VI, Ochoa GC, Butler MH, De Camilli P. Tandem arrangement of the clathrin and AP-2 binding domains in amphiphysin 1 and disruption of clathrin coat function by amphiphysin fragments comprising these sites. J Biol Chem 2000; 275: 17583-9.
217. Hinshaw JE. Dynamin and its role in membrane fission. Annu Rev Cell Dev Biol 2000; 16: 483-519.
218. Horikawa HP, Kneussel M, El Far O, Betz H. Interaction of synaptophysin with the AP-1 adaptor protein gamma-adaptin. Mol Cell Neurosci 2002; 21: 454-62.
219. Worby CA, Dixon JE. Sorting out the cellular functions of sorting nexins. Nat Rev Mol Cell Biol 2002; 3: 919-31.
220. Wang Y, Zhou Y, Szabo K, Haft CR, Trejo J. Down-regulation of protease-activated receptor-1 is regulated by sorting nexin 1. Mol Biol Cell 2002; 13: 1965-76.
221. Gullapalli A, Wolfe BL, Griffin CT, Magnuson T, Trejo J. An essential role for SNX1 in lysosomal sorting of protease-activated receptor-1: evidence for retromer-, Hrs-, and Tsg101-independent functions of sorting nexins. Mol Biol Cell 2006; 17: 1228-38.
222. Yan Y, Lagenaur C, Narayanan V. Molecular cloning of M6: identification of a PLP/DM20 gene family. Neuron 1993; 11: 423-31.
223. Yan Y, Narayanan V, Lagenaur C. Expression of members of the proteolipid protein gene family in the developing murine central nervous system. J Comp Neurol 1996; 370: 465-78.
224. Roussel G, Trifilieff E, Lagenaur C, Nussbaum JL. Immunoelectron microscopic localization of the M6a antigen in rat brain. J Neurocytol 1998; 27: 695-703.
225. Lagenaur C, Kunemund V, Fischer G, Fushiki S, Schachner M. Monoclonal M6 antibody interferes with neurite extension of cultured neurons. J Neurobiol 1992; 23: 71-88.
226. Alfonso J, Fernandez ME, Cooper B, Flugge G, Frasch AC. The stress-regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation. Proc Natl Acad Sci U S A 2005; 102: 17196-201.
227. Mukobata S, Hibino T, Sugiyama A, et al. M6a acts as a nerve growth factor-gated Ca(2+) channel in neuronal differentiation. Biochem Biophys Res Commun 2002; 297: 722-8.
228. Wu DF, Koch T, Liang YJ, et al. Membrane glycoprotein M6a interacts with the micro-opioid receptor and facilitates receptor endocytosis and recycling. J Biol Chem 2007; 282: 22239-47.
229. Liang YJ, Wu DF, Stumm R, Hollt V, Koch T. Membrane glycoprotein M6A promotes mu-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway. Cell Res 2008; 18: 768-79.
230. Petaja-Repo UE, Hogue M, Laperriere A, Bhalla S, Walker P, Bouvier M. Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. J Biol Chem 2001; 276: 4416-23.
231. Tanowitz M, Von Zastrow M. Ubiquitination-independent trafficking of G protein-coupled receptors to lysosomes. J Biol Chem 2002; 277: 50219-22.
232. Hislop JN, Henry AG, Marchese A, von Zastrow M. Ubiquitination regulates proteolytic processing of G protein-coupled receptors after their sorting to lysosomes. J Biol Chem 2009; 284: 19361-70.
233. Chaturvedi K, Bandari P, Chinen N, Howells RD. Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors. J Biol Chem 2001; 276: 12345-55.
234. Tanowitz M, von Zastrow M. A novel endocytic recycling signal that distinguishes the membrane trafficking of naturally occurring opioid receptors. J Biol Chem 2003; 278: 45978-86.
235. Li JG, Haines DS, Liu-Chen LY. Agonist-promoted Lys63-linked polyubiquitination of the human kappa-opioid receptor is involved in receptor down-regulation. Mol Pharmacol 2008; 73: 1319-30.
236. Liu-Chen LY. Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 2004; 75: 511-36.
237. Li JG, Benovic JL, Liu-Chen LY. Mechanisms of agonist-induced down-regulation of the human kappa-opioid receptor: internalization is required for down-regulation. Mol Pharmacol 2000; 58: 795-801.
238. Li JG, Chen C, Liu-Chen LY. Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human kappa opioid receptor by enhancing its recycling rate. J Biol Chem 2002; 277: 27545-52.
239. Hall RA, Ostedgaard LS, Premont RT, et al. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci U S A 1998; 95: 8496-501.
240. Hall RA, Premont RT, Chow CW, et al. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature 1998; 392: 626-30.
241. Cao TT, Deacon HW, Reczek D, Bretscher A, von Zastrow M. A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-adrenergic receptor. Nature 1999; 401: 286-90.
242. Huang P, Steplock D, Weinman EJ, et al. kappa Opioid receptor interacts with Na(+)/H(+)-exchanger regulatory factor-1/Ezrinradixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na(+)/H(+) exchange independent of G(i)/G(o) proteins. J Biol Chem 2004; 279: 25002-9.
243. Mahon MJ, Segre GV. Stimulation by parathyroid hormone of a NHERF-1-assembled complex consisting of the parathyroid hormone I receptor, phospholipase Cbeta, and actin increases intracellular calcium in opossum kidney cells. J Biol Chem 2004; 279: 23550-8.
244. Chen C, Li JG, Chen Y, Huang P, Wang Y, Liu-Chen LY. GEC1 interacts with the kappa opioid receptor and enhances expression of the receptor. J Biol Chem 2006; 281: 7983-93.
245. Pellerin I, Vuillermoz C, Jouvenot M, Ordener C, Royez M, Adessi GL. Identification and characterization of an early estrogenregulated RNA in cultured guinea-pig endometrial cells. Mol Cell Endocrinol 1993; 90: R17-21.
246. Wang Y, Dun SL, Huang P, et al. Distribution and ultrastructural localization of GEC1 in the rat CNS. Neuroscience 2006; 140: 1265-76.
247. Chen Y, Chen C, Kotsikorou E, Lynch DL, Reggio PH, Liu-Chen LY. GEC1-kappa opioid receptor binding involves hydrophobic interactions: GEC1 has chaperone-like effect. J Biol Chem 2009; 284: 1673-85.
248. Ge X, Loh HH, Law PY. mu-Opioid receptor cell surface expression is regulated by its direct interaction with Ribophorin I. Mol Pharmacol 2009; 75: 1307-16.
249. Kreibich G, Freienstein CM, Pereyra BN, Ulrich BL, Sabatini DD. Proteins of rough microsomal membranes related to ribosome binding. II. Cross-linking of bound ribosomes to specific membrane proteins exposed at the binding sites. J Cell Biol 1978; 77: 488-506.
250. Wilson CM, High S. Ribophorin I acts as a substrate-specific facilitator of N-glycosylation. J Cell Sci 2007; 120: 648-57.
251. de Virgilio M, Weninger H, Ivessa NE. Ubiquitination is required for the retro-translocation of a short-lived luminal endoplasmic reticulum glycoprotein to the cytosol for degradation by the proteasome. J Biol Chem 1998; 273: 9734-43.
252. Wilson CM, Kraft C, Duggan C, Ismail N, Crawshaw SG, High S. Ribophorin I associates with a subset of membrane proteins after their integration at the sec61 translocon. J Biol Chem 2005; 280: 4195-206.
253. Onoprishvili I, Andria ML, Kramer HK, Ancevska-Taneva N, Hiller JM, Simon EJ. Interaction between the mu opioid receptor and filamin A is involved in receptor regulation and trafficking. Mol Pharmacol 2003; 64: 1092-100.
254. Stossel TP, Condeelis J, Cooley L, et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol 2001; 2: 138-45.
255. Loo DT, Kanner SB, Aruffo A. Filamin binds to the cytoplasmic domain of the beta1-integrin. Identification of amino acids responsible for this interaction. J Biol Chem 1998; 273: 23304-12.
256. Zhang W, Han SW, McKeel DW, Goate A, Wu JY. Interaction of presenilins with the filamin family of actin-binding proteins. J Neurosci 1998; 18: 914-22.
257. Li M, Li C, Weingarten P, Bunzow JR, Grandy DK, Zhou QY. Association of dopamine D(3) receptors with actin-binding protein 280 (ABP-280). Biochem Pharmacol 2002; 63: 859-63.
258. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci U S A 2001; 98: 5258-63.
259. Awata H, Huang C, Handlogten ME, Miller RT. Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein. J Biol Chem 2001; 276: 34871-9.
260. Hjalm G, MacLeod RJ, Kifor O, Chattopadhyay N, Brown EM. Filamin-A binds to the carboxyl-terminal tail of the calciumsensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase. J Biol Chem 2001; 276: 34880-7.
261. Enz R. The actin-binding protein Filamin-A interacts with the metabotropic glutamate receptor type 7. FEBS Lett 2002; 514: 184-8.
262. Seck T, Baron R, Horne WC. Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J Biol Chem 2003; 278: 10408-16.
263. Onoprishvili I, Simon EJ. Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A. Brain Res 2007; 1177: 9-18.
264. Onoprishvili I, Ali S, Andria ML, Shpigel A, Simon EJ. Filamin A mutant lacking actin-binding domain restores mu opioid receptor regulation in melanoma cells. Neurochem Res 2008; 33: 2054-61.
265. Wang HY, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS One 2008; 3: e1554.
266. Wang HY, Burns LH. Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One 2009; 4: e4282.
267. Guan JS, Xu ZZ, Gao H, et al. Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia. Cell 2005; 122: 619-31.
268. Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J 1990; 4: 1606-15.
269. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765-9.
270. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 2004; 101: 5135-9.
271. Zhang X, Bao L, Ma GQ. Sorting of neuropeptides and neuropeptide receptors into secretory pathways. Prog Neurobiol 90: 276-83.
272. Scherrer G, Imamachi N, Cao YQ, et al. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009; 137: 1148-59.
273. Ancevska-Taneva N, Onoprishvili I, Andria ML, Hiller JM, Simon EJ. A member of the heat shock protein 40 family, hlj1, binds to the carboxyl tail of the human mu opioid receptor. Brain Res 2006; 1081: 28-33.
274. Ohtsuka K. Cloning of a cDNA for heat-shock protein hsp40, a human homologue of bacterial DnaJ. Biochem Biophys Res Commun 1993; 197: 235-40.
275. Siffroi-Fernandez S, Giraud A, Lanet J, Franc JL. Association of the thyrotropin receptor with calnexin, calreticulin and BiP. Efects on the maturation of the receptor. Eur J Biochem 2002; 269: 4930-7.
276. Lanctot PM, Leclerc PC, Clement M, et al. Importance of Nglycosylation positioning for cell-surface expression, targeting, affinity and quality control of the human AT1 receptor. Biochem J 2005; 390: 367-76.
277. Wannemacher KM, Terskiy A, Bian S, Yadav PN, Li H, Howells RD. Purification and mass spectrometric analysis of the kappa opioid receptor. Brain Res 2008; 1230: 13-26.
278. Leskela TT, Markkanen PM, Pietila EM, Tuusa JT, Petaja-Repo UE. Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum. J Biol Chem 2007; 282: 23171-83.
279. Petaja-Repo UE, Hogue M, Bhalla S, Laperriere A, Morello JP, Bouvier M. Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J 2002; 21: 1628-37.
280. Guillet-Deniau I, Burnol AF, Girard J. Identification and localization of a skeletal muscle secrotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J Biol Chem 1997; 272: 14825-9.
281. Sasaguri T, Teruya H, Ishida A, Abumiya T, Ogata J. Linkage between alpha(1) adrenergic receptor and the Jak/STAT signaling pathway in vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 268: 25-30.
282. Marrero MB, Schieffer B, Paxton WG, Duff JL, Berk BC, Bernstein KE. The role of tyrosine phosphorylation in angiotensin II-mediated intracellular signalling. Cardiovasc Res 1995; 30: 530-6.
283. McWhinney CD, Dostal D, Baker K. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes. J Mol Cell Cardiol 1998; 30: 751-61.
284. Georganta EM, Agalou A, Georgoussi Z. Multi-component signaling complexes of the delta-opioid receptor with STAT5B and G proteins. Neuropharmacology 2010; 59: 139-48.
285. Ali MS, Sayeski PP, Dirksen LB, Hayzer DJ, Marrero MB, Bernstein KE. Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J Biol Chem 1997; 272: 23382-8.
286. Fan G, Shumay E, Malbon CC, Wang H. c-Src tyrosine kinase binds the beta 2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization. J Biol Chem 2001; 276: 13240-7.
287. Ram PT, Iyengar R. G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene 2001; 20: 1601-6.
288. Zhang F, Wang S, Cao G, Gao Y, Chen J. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis 2007; 25: 45-53.
289. Dziennis S, Alkayed NJ. Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration. Rev Neurosci 2008; 19: 341-61.
290. Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994; 14: 5559-69.
291. Gonzalez MI, Robinson MB. Neurotransmitter transporters: why dance with so many partners? Curr Opin Pharmacol 2004; 4: 30-5.
292. Xia P, Pei G, Schwarz W. Regulation of the glutamate transporter EAAC1 by expression and activation of delta-opioid receptor. Eur J Neurosci 2006; 24: 87-93.
293. Thorlin T, Roginski RS, Choudhury K, et al. Regulation of the glial glutamate transporter GLT-1 by glutamate and delta-opioid receptor stimulation. FEBS Lett 1998; 425: 453-9.
294. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22: 8312-23.
295. Xu NJ, Bao L, Fan HP, et al. Morphine withdrawal increases glutamate uptake and surface expression of glutamate transporter GLT1 at hippocampal synapses. J Neurosci 2003; 23: 4775-84.
296. Guo M, Xu NJ, Li YT, Yang JY, Wu CF, Pei G. Morphine modulates glutamate release in the hippocampal CA1 area in mice. Neurosci Lett 2005; 381: 12-5.